Skip to main content
Fig. 5 | Translational Medicine Communications

Fig. 5

From: Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy

Fig. 5

TAPA-specific T-cell response. The TAPA-specific activation of PBMCs-derived T-cells was measured by flow-cytometry by evaluating the number of CD8 + CD137+ events per 10,000 PBMCs exposed to the indicated peptides. Results show average (+/− 95% C.I.) out of triplicate measurements, obtained from PBMCs taken at baseline (before the first vaccine dose), and after the third dose of vaccine. For each peptide stimulus, a two-way t test (alpha = 0.05) was performed to compare the mean CD8 + CD137+ numbers or the mean IP-10 levels between baseline and post-third vaccine (**, p < 0.01; ***, p < 0.001; NS, not significant). The horizontal lines in the upper panels indicate the number of total CD8+ event /10,000 cells before the stimulation with the peptides in vitro (regardless of CD137 expression)

Back to article page